Abcellera twitter sentiment

Twitter users highlight Veozah (Fezolinetant) 3--phase data showing CNS safety similar to placebo, validating NK3R market for hot flashes but with liver monitoring burden; this indirectly positive for $ABCL's ABCL635 (same target, antibody with no liver tox in Ph1, potential monthly dosing) as differentiation if efficacy matches in Q3 2026 Ph2.

Sources